EU Joint Clinical Assessment: First High-Risk Medical Devices Selected Under HTAR

On October 6, 2026, the European Commission selected the first group of high-risk medical devices to undergo a Joint Clinical Assessment (JCA) under the new EU Health Technology Assessment Regulation (HTAR). This episode explains what this pivotal moment means for medical device manufacturers, which device categories are impacted, and how the JCA will reshape the pathway for pricing, reimbursement, and market access across the European Union. We discuss the heightened evidence requirements and provide practical steps for regulatory and market access teams to prepare for this new centralized assessment system. Key Questions: - What is the EU Joint Clinical Assessment (JCA) and why is it critical for medical device manufacturers? - Which types of high-risk medical devices were part of the first selection on October 6, 2026? - How will the JCA report influence national reimbursement and pricing decisions? - What is the difference between a CE marking submission and a JCA dossier? - What are the new clinical evidence requirements under the Health Technology Assessment Regulation (HTAR)? - How should companies adjust their clinical development strategies for future devices? - What are the immediate actions regulatory teams should take to prepare for a JCA? - When will the HTAR requirements expand to include other Class III and IIb devices? Sources: - https://health.ec.europa.eu/latest-updates/hta-regulation-commission-selects-first-medical-devices-joint-clinical-assessment-2026-10-06_en How Pure Global can help: Pure Global provides comprehensive support for MedTech and IVD companies navigating complex regulatory landscapes like the EU's new HTAR. Our experts develop robust regulatory and market access strategies, ensuring your clinical evidence meets the rigorous demands of Joint Clinical Assessments. We use advanced AI tools to efficiently compile and manage the technical dossiers required for both CE marking and JCA submissions, reducing time-to-market and compliance risks. With a presence in over 30 markets, we act as your local representative and provide continuous monitoring to keep you ahead of regulatory changes. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai to accelerate your global growth.